Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.52 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10266678 | 0.80 | NOTUM (0.55) | NOTUMKDM4EALDH1A1PPARGSTAT3 | |
| SCHEMBL2492377 | 0.79 | NOTUM (0.46) | NOTUM | |
| SCHEMBL29664535 | 0.78 | ALDH1A1 (0.68) | NOTUMKDM4EALDH1A1PPARGSTAT3 | |
| SCHEMBL18394492 | 0.78 | ALDH1A1 (0.68) | NOTUMKDM4EALDH1A1PPARGSTAT3 | |
| SCHEMBL7301708 | 0.78 | NOTUM (0.62) | NOTUMMAOB | |
| SCHEMBL24548630 | 0.77 | NOTUM (0.50) | NOTUMKDM4EALDH1A1 | |
| SCHEMBL7454214 | 0.75 | NOTUM (0.64) | NOTUMKDM4EALDH1A1PPARGNCOA2 | |
| SCHEMBL29717244 | 0.74 | NOTUM (0.49) | NOTUM | |
| SCHEMBL29009434 | 0.73 | SGMS2 (0.55) | BRD4SGMS2IDO1MAOBPTGER1 | |
| SCHEMBL30427902 | 0.73 | SGMS2 (0.55) | BRD4SGMS2IDO1MAOBPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183384-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90B1, HSP90AA1 | BRD4 177/4885NOTUM 3888/4885SGMS2 4585/4885 |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | BRD4 177/4885NOTUM 3888/4885SGMS2 4585/4885 |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | BRD4 177/4885NOTUM 3888/4885SGMS2 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.